Inbec售价多少一盒?
Suimeike (Dolutea Paramid Tablets, Inbec) was approved by the US FDA in 2014 for the treatment of adults and adolescents over 12 years old (weight not less than 40 kilograms) infected with human immunodeficiency virus (HIV, also called AIDS). On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation Suimeike (dolute abalamib tablets, Inbec) was officially launched in mainland China. Suimeikai (Domitabalamid Tablets, Inbec) has officially begun to provide new treatment options for HIV patients in my country. This is the best-selling drug for the treatment of AIDS in my country in the past five years and plays an important role in the field of AIDS treatment.
Suimeikai (dolutegravir tablets, Inbec) is a compound preparation that mainly contains three ingredients, namely dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. One tablet is a complete treatment regimen. Moreover, the method of use of Suimeikai is simple. One tablet a day can achieve the effect of cocktail therapy without food restrictions, which greatly improves the patient's medication compliance. In terms of therapeutic effect, it can also significantly inhibit the virus, has smaller side effects, and is less likely to develop drug resistance.
After Suimeikai (Domitabalamid Tablets, Inbec) was launched in my country, what many patients are most eager to know is: What is the price of Suimeike (Domitabalamid Tablets, Inbec) in 2020? The current price of Suimeikai (Abalamid Tablets, Inbec) in the Chinese market is 2,880$/month. Since they have not yet entered into medical insurance, many patients face great financial pressure if they need to take medication for a long time. You may wish to choose Suimeike (Abalamid Tablets, Inbec) produced by the Indian company Emcure. There are 30 tablets in a box and the price is equivalent to RMB 1,000. This is currently the most cost-effective one.
The above is the price of Suimeikai (Domitabalamid Tablets, Inbec) provided to you by our Medical Companion Travel Overseas Medical Consulting Service Company.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)